Is It Better To Be First Or Best? Daiichi Sankyo Shifts R&D Priorities
This article was originally published in The Pink Sheet Daily
Because regulators and the market have become less accepting of follow-on compounds, the Japanese pharma plans to invest in first-in-class science, pursuing best-in-class opportunities only when it sees a substantial unmet medical need.
You may also be interested in...
Rivaroxaban misses two bleeding safety measures, and debate heats up on whether it showed superior efficacy against warfarin.
TOKYO - Daiichi Sankyo announced July 12 its factor Xa inhibitor edoxaban posted superior results to Sanofi-Aventis' Lovenox (enoxaparin), a low dose heparin, in preventing venous thromboembolic events in patients following total knee replacement. The announcement will put Daiichi Sankyo's marketing chops to the test, as the compound, while clear in its efficacy, is primed to enter a market with a number of potential factor Xa competitors in a Japanese antithrombotic market still dominated by heparin and warfarin
TOKYO - As expected, top Japanese pharmaceutical players have reported lackluster April-June earnings as they struggled under the strong yen's weight, with three leading firms reiterating efforts to expedite launching products now in the pipelines